Compound: 
GBR 1342
Primary Indications: 
Multiple myeloma, Solid Tumors
Target: 
CD38xCD3 (bispecific mAb)
details: 

GBR 1342, a CD38xCD3 bsAb based on Glenmark’s proprietary BEAT platform targets CD38, a clinical target in multiple myeloma and other malignancies of hematopoietic origin, as well as a variety of solid tumors. Results from preclinical assays in comparison to daratumumab, an FDA-approved monoclonal antibody targeting CD38, suggest that GBR 1342 has a potent antitumor effect on patient derived multiple myeloma cell lines.

Percentage Completed: 
30.00
biological entity: 
Oncology